The severity often exceeds that observed in classical MG among patients receiving anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and anti-programmed cell death protein 1 (PD-1) therapies [7]. This evidence concerns the gene CTLA4 and myasthenia gravis.